Clinical Trial Update: Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS [Phase 2]

View source ↗

Summary

Phase 2 study of efgartigimod in adults with Postural Orthostatic Tachycardia Syndrome (POTS) linked to prior COVID-19 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postural Orthostatic Tachycardia Syndrome

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Postural Orthostatic Tachycardia Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-05-23